DOCSLIB.ORG

Prior Authorization Gonadotropin-Releasing Hormone Agonists Implant - Zoladex® (Goserelin Acetate Subcutaneous Implant)

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Prior Authorization Gonadotropin-Releasing Hormone Agonists Implant - Zoladex® (Goserelin Acetate Subcutaneous Implant) Cigna National Formulary Coverage Policy Prior Authorization Gonadotropin-Releasing Hormone Agonists Implant - Zoladex® (goserelin acetate subcutaneous implant) Table of Contents Product Identifer(s) National Formulary Medical Necessity ................ 1 66292 Conditions Not Covered....................................... 2 Background .......................................................... 2 References .......................................................... 3 Revision History ................................................... 3 INSTRUCTIONS FOR USE The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations. National Formulary Medical Necessity Cigna covers goserelin acetate (Zoladex®) as medically necessary when the following criteria are met for FDA Indications or Other Uses with Supportive Evidence: Prior Authorization is recommended for prescription benefit coverage of Zoladex. All approvals are provided for the duration noted below. In cases where the approval is authorized in months, 1 month is equal to 30 days. Because of the specialized skills required for evaluation and diagnosis of individuals treated with Zoladex as well as the monitoring required for adverse events and long-term efficacy, approval requires this agent to be prescribed by or in consultation with a physician who specializes in the condition being treated. Coverage of Zoladex is recommended in individuals who meet one of the following criteria: FDA Indication(s) 1. Abnormal Uterine Bleeding. Approve for up to 2 months (total) if the individual meets the following conditions (A and B): A) Zoladex is used as an endometrial-thinning agent prior to endometrial ablation; AND Page 1 of 3 Cigna National Formulary Coverage Policy: PA Gonadotropin-Releasing Hormone Agonists Implant - Zoladex B) The medication is prescribed by or in consultation with an obstetrician-gynecologist or a healthcare practitioner who specializes in the treatment of women’s health. 2. Breast Cancer. Approve for 1 year if the individual meets the following conditions (A and B): A) Zoladex is used in premenopausal or perimenopausal women; AND B) The medication is prescribed by or in consultation with an oncologist. 3. Endometriosis. Approve for up to 6 months (total) if the individual meets the following conditions (A and B): A) Individual is ≥ 18 years of age; AND B) The medication is prescribed by or in consultation with an obstetrician-gynecologist or a healthcare practitioner who specializes in the treatment of women’s health. 4. Prostate Cancer. Approve for 1 year if the medication is prescribed by or in consultation with an oncologist. Conditions Not Covered Goserelin acetate (Zoladex®) is considered experimental, investigational or unproven for ANY other use including the following (this list may not be all inclusive): 1. Peripheral Precocious Puberty (also known as GnRH-independent precocious puberty). Children with peripheral precocious puberty do not respond to GnRH agonist therapy.6 Treatment is directed at removing or blocking the production and/or response to the excess sex steroids, depending on the cause (e.g., surgically removing human chorionic gonadotropin-secreting tumors or using glucocorticoids to treat defects in adrenal steroidogenesis [such as classic congenital adrenal hyperplasia]). Background Overview Zoladex is a gonadotropin-releasing hormone (GnRH) agonists implant.1-2 Zoladex is indicated for the following conditions:1,2 • Breast cancer, palliative treatment of advanced breast cancer in pre- and perimenopausal women (Zoladex 3.6 mg implant only). • Endometrial-thinning, use as an endometrial-thinning agent prior to endometrial ablation for dysfunctional uterine bleeding (Zoladex 3.6 mg implant only). • Endometriosis, including pain relief and reduction of endometriotic lesions for the duration of therapy (Zoladex 3.6 mg implant only). • Prostate cancer, in combination with flutamide for the management of locally confined Stage T2b-T4 (Stage B2-C). • Prostate cancer, palliative treatment. Guidelines The NCCN Breast Cancer guidelines (version 6.2020 – September 8, 2020) does not note the use of Zoladex implants for advanced breast cancer.3 However, the guidelines note that GnRH agonists (e.g., Zoladex) administered prior to initiating chemotherapy protect against ovarian failure and reduce the risk of early menopause. Central precocious puberty, also known as gonadotropin-dependent precocious puberty, is caused by early maturation of the hypothalamic-pituitary-gonadal axis.4 The standard of care for central precocious puberty is GnRH agonists. The European Society for Paediatric Endocrinology and the Lawson Wilkins Pediatric Endocrine Society convened a consensus conference (2009) to review the use of GnRH agonists in pediatric patients with central precocious puberty.5 The panel noted that the available GnRH agonists (including leuprolide, triptorelin, and histrelin implant) are effective despite different routes of administration, dosing, and duration of action. An update by the International Consortium (2019) reiterates the use of GnRH agonists (e.g., Page 2 of 3 Cigna National Formulary Coverage Policy: PA Gonadotropin-Releasing Hormone Agonists Implant - Zoladex leuprolide, triptorelin, and histrelin implant) for the treatment of central precocious puberty.6 GnRH agonists are generally well-tolerated in children and adolescents. The National Comprehensive Cancer Network (NCCN) Prostate Cancer guidelines (version 3.2020 – November 17, 2020) lists Zoladex as an androgen deprivation therapy (ADT) option for use in various settings (all category 2A): clinically localized disease, regional disease, prostate specific antigen (PSA) persistence/recurrence after radical prostatectomy (RP) or external beam radiation therapy (EBRT) [castration-naïve disease], and metastatic castration-naïve disease.7 References 1. Zoladex® 3.6 mg Implant [prescribing information]. Lake Forest, IL: TerSera Therapeutics; February 2019. 2. Zoladex® 10.8 mg Implant [prescribing information]. Lake Forest, IL: TerSera Therapeutics; February 2019. 3. The NCCN Breast Cancer Clinical Practice Guidelines in Oncology (Version 6.2020 – September 8, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on January 14, 2021. 4. Eugster EA. Treatment of central precocious puberty. J Endo Soc. 2019;3:965-972. 5. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics. 2009 Apr;123(4):e752-62. 6. Krishna KB, Fuqua JS, Rogol AD, et al. Use of gonadotropin-releasing hormone analogs in children: update by an international consortium. Horm Res Paediatr. 2019;91:357-372. 7. The NCCN Prostate Cancer Clinical Practice Guidelines in Oncology (Version3.2020 – November 17, 2020). © 2020 National Comprehensive Cancer Network, Inc. Available at: http://www.nccn.org. Accessed on January 14, 2021. Revision History Type of Summary of Changes Review Date Revision Annual Revision No criteria changes. 01/20/2021 “Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna. Page 3 of 3 Cigna National Formulary Coverage Policy: PA Gonadotropin-Releasing Hormone Agonists Implant - Zoladex .
Load more

Recommended publications
  • A Comparison of the Costs for Treating Central Precocious Puberty During the First Year with Monthly Leuprolide Acetate Injectable and Histrelin Acetate Implant
    A Comparison Of The Costs For Treating Central Precocious Puberty During The First Year With Monthly Leuprolide Acetate Injectable And Histrelin Acetate Implant B F Banahan III1, Mayo K2, Summers KH2 1 Center for Pharmaceutical Marketing and Management and Department of Pharmacy Administration, University of Mississippi, University, MS 2 Health Outcomes & PharmacoEconomics, Endo Pharmaceuticals, Inc., Chadds Ford, PA Estimated Annual Cost of Treatment if all PTs Treated With . BACKGROUND METHODS MEDICAID MODEL Lupron SUPPRELIN LA Product costs $ 1,770,201 $ 1,515,188 Two retrospective cohort studies were conducted using datasets derived from the Office visit costs $ 79,896 $ 14,000 Puberty results when secretion of gonadotropin releasing hormone (GnRH) is initiated 100% compliance with Lupron treatment 1 Implant procedures $ 91,400 and the hypothalamic-pituitary-gonadal axis is activated. During puberty, the brain Thomas Reuter’s MarketScan© Multi-State Medicaid Database (2003-2007) and the (All patients receive 13+ treatments in year) MarketScan© Commercial Database (2005-2009). A probabilistic patient flow model Lab/xray for monitoring $ 53,900 $ 37,500 produces GnRH through a complex process. GnRH causes increases in other TOTAL COST TO PAYER $ 1,903,997 $ 1,658,088 hormones like luteinizing hormone (LH) and follicle stimulating hormone (FSH). It is was developed using estimates for treatment patterns and costs for products, office Normal Compliance with Lupron: Lupron SUPPRELIN LA these hormones that cause the ovaries to produce estrogen and the testicles to visits, and monitoring therapy. Patients with < 13 treatments per year Product costs $ 1,572,921 $ 1,515,188 Quality of Care ofCare Quality % of TXd PTs: 53% Aver.
    [Show full text]
  • Hormones and Breeding
    IN-DEPTH: REPRODUCTIVE ENDOCRINOLOGY Hormones and Breeding Carlos R.F. Pinto, MedVet, PhD, Diplomate ACT Author’s address: Theriogenology and Reproductive Medicine, Department of Veterinary Clinical Sciences, College of Veterinary Medicine, The Ohio State University, Columbus, OH 43210; e-mail: [email protected]. © 2013 AAEP. 1. Introduction affected by PGF treatment to induce estrus. In The administration of hormones to mares during other words, once luteolysis takes place, whether breeding management is an essential tool for equine induced by PGF treatment or occurring naturally, practitioners. Proper and timely administration of the events that follow (estrus behavior, ovulation specific hormones to broodmares may be targeted to and fertility) are essentially similar or minimally prevent reproductive disorders, to serve as an aid to affected (eg, decreased signs of behavioral estrus). treating reproductive disorders or hormonal imbal- Duration of diestrus and interovulatory intervals ances, and to optimize reproductive efficiency, for are shortened after PGF administration.1 The example, through induction of estrus or ovulation. equine corpus luteum (CL) is responsive to PGF These hormones, when administered exogenously, luteolytic effects any day after ovulation; however, act to control the duration and onset of the different only CL Ͼ5 days are responsive to one bolus injec- stages of the estrous cycle, specifically by affecting tion of PGF.2,3 Luteolysis or antiluteogenesis can duration of luteal function, hastening ovulation es- be reliably achieved in CL Ͻ5 days only if multiple pecially for timed artificial insemination and stimu- PGF treatments are administered. For that rea- lating myometrial activity in mares susceptible to or son, it became a widespread practice to administer showing delayed uterine clearance.
    [Show full text]
  • CASODEX (Bicalutamide)
    HIGHLIGHTS OF PRESCRIBING INFORMATION • Gynecomastia and breast pain have been reported during treatment with These highlights do not include all the information needed to use CASODEX 150 mg when used as a single agent. (5.3) CASODEX® safely and effectively. See full prescribing information for • CASODEX is used in combination with an LHRH agonist. LHRH CASODEX. agonists have been shown to cause a reduction in glucose tolerance in CASODEX® (bicalutamide) tablet, for oral use males. Consideration should be given to monitoring blood glucose in Initial U.S. Approval: 1995 patients receiving CASODEX in combination with LHRH agonists. (5.4) -------------------------- RECENT MAJOR CHANGES -------------------------- • Monitoring Prostate Specific Antigen (PSA) is recommended. Evaluate Warnings and Precautions (5.2) 10/2017 for clinical progression if PSA increases. (5.5) --------------------------- INDICATIONS AND USAGE -------------------------- ------------------------------ ADVERSE REACTIONS ----------------------------- • CASODEX 50 mg is an androgen receptor inhibitor indicated for use in Adverse reactions that occurred in more than 10% of patients receiving combination therapy with a luteinizing hormone-releasing hormone CASODEX plus an LHRH-A were: hot flashes, pain (including general, back, (LHRH) analog for the treatment of Stage D2 metastatic carcinoma of pelvic and abdominal), asthenia, constipation, infection, nausea, peripheral the prostate. (1) edema, dyspnea, diarrhea, hematuria, nocturia, and anemia. (6.1) • CASODEX 150 mg daily is not approved for use alone or with other treatments. (1) To report SUSPECTED ADVERSE REACTIONS, contact AstraZeneca Pharmaceuticals LP at 1-800-236-9933 or FDA at 1-800-FDA-1088 or ---------------------- DOSAGE AND ADMINISTRATION ---------------------- www.fda.gov/medwatch The recommended dose for CASODEX therapy in combination with an LHRH analog is one 50 mg tablet once daily (morning or evening).
    [Show full text]
  • Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals
    Journal of Clinical Medicine Review Hormonal Treatment Strategies Tailored to Non-Binary Transgender Individuals Carlotta Cocchetti 1, Jiska Ristori 1, Alessia Romani 1, Mario Maggi 2 and Alessandra Daphne Fisher 1,* 1 Andrology, Women’s Endocrinology and Gender Incongruence Unit, Florence University Hospital, 50139 Florence, Italy; [email protected] (C.C); jiska.ristori@unifi.it (J.R.); [email protected] (A.R.) 2 Department of Experimental, Clinical and Biomedical Sciences, Careggi University Hospital, 50139 Florence, Italy; [email protected]fi.it * Correspondence: fi[email protected] Received: 16 April 2020; Accepted: 18 May 2020; Published: 26 May 2020 Abstract: Introduction: To date no standardized hormonal treatment protocols for non-binary transgender individuals have been described in the literature and there is a lack of data regarding their efficacy and safety. Objectives: To suggest possible treatment strategies for non-binary transgender individuals with non-standardized requests and to emphasize the importance of a personalized clinical approach. Methods: A narrative review of pertinent literature on gender-affirming hormonal treatment in transgender persons was performed using PubMed. Results: New hormonal treatment regimens outside those reported in current guidelines should be considered for non-binary transgender individuals, in order to improve psychological well-being and quality of life. In the present review we suggested the use of hormonal and non-hormonal compounds, which—based on their mechanism of action—could be used in these cases depending on clients’ requests. Conclusion: Requests for an individualized hormonal treatment in non-binary transgender individuals represent a future challenge for professionals managing transgender health care. For each case, clinicians should balance the benefits and risks of a personalized non-standardized treatment, actively involving the person in decisions regarding hormonal treatment.
    [Show full text]
  • Hertfordshire Medicines Management Committee (Hmmc) Nafarelin for Endometriosis Amber Initiation – Recommended for Restricted Use
    HERTFORDSHIRE MEDICINES MANAGEMENT COMMITTEE (HMMC) NAFARELIN FOR ENDOMETRIOSIS AMBER INITIATION – RECOMMENDED FOR RESTRICTED USE Name: What it is Indication Date Decision NICE / SMC generic decision status Guidance (trade) last revised Nafarelin A potent agonistic The hormonal December Final NICE NG73 2mg/ml analogue of management of 2020 Nasal Spray gonadotrophin endometriosis, (Synarel®) releasing hormone including pain relief and (GnRH) reduction of endometriotic lesions HMMC recommendation: Amber initiation across Hertfordshire (i.e. suitable for primary care prescribing after specialist initiation) as an option in endometriosis Background Information: Gonadorelin analogues (or gonadotrophin-releasing hormone agonists [GnRHas]) include buserelin, goserelin, leuprorelin, nafarelin and triptorelin. The current HMMC decision recommends triptorelin as Decapeptyl SR® injection as the gonadorelin analogue of choice within licensed indications (which include endometriosis) link to decision. A request was made by ENHT to use nafarelin nasal spray as an alternative to triptorelin intramuscular injection during the COVID-19 pandemic. The hospital would provide initial 1 month supply, then GPs would continue for further 5 months as an alternative to the patient attending for further clinic appointments for administration of triptorelin. Previously at ENHT, triptorelin was the only gonadorelin analogue on formulary for gynaecological indications. At WHHT buserelin nasal spray 150mcg/dose is RED (hospital only) for infertility & endometriosis indications. Nafarelin nasal spray 2mg/ml is licensed for: . The hormonal management of endometriosis, including pain relief and reduction of endometriotic lesions. Use in controlled ovarian stimulation programmes prior to in-vitro fertilisation, under the supervision of an infertility specialist. Use of nafarelin in endometriosis aims to induce chronic pituitary desensitisation, which gives a menopause-like state maintained over many months.
    [Show full text]
  • Altered Cognitive Function in Men Treated for Prostate
    Altered Cognitive Function in Men Treated for Prostate Cancer with LHRH Analogues and Cyproterone Acetate: A Randomised Controlled Trial H. J. Green PhD1,2, K. I. Pakenham PhD1, B. C. Headley PhD3, J. Yaxley FRACS3, D. L. Nicol FRACS2,4, P. N. Mactaggart FRACS2,5, C. Swanson PhD2, R. B. W atson FRACS6, & R. A. Gardiner MD2,3 1School of Psychology and 2Department of Surgery, The University of Queensland, 3Royal Brisbane, 4Princess Alexandra, 5Queen Elizabeth II & 6Mater Hospitals, Brisbane, Queensland, Australia In conjunction with the Northern Section of the Urological Society of Australasia Correspondence should be addressed to: Dr R. A. Gardiner, Department of Surgery, The University of Queensland, Brisbane, Qld 4072, Australia Fax: +61 7 3365 5559; Phone: +61 7 3365 5233; Email: f.gardiner@ mailbox.uq.edu.au This work was wholly funded by Queensland Cancer Fund. **PREPRINT. Final version published in British Journal of Urology (BJU: International) (2002), 90, 427-432 ** Short Title: COGNITIVE CHANGES W ITH HORMONAL MEDICATION 2 Objective. Luteinising hormone releasing hormone (LHRH) analogues have been associated with memory impairments in women using these drugs for gynaecological conditions. This is the first systematic investigation of the cognitive effects of LHRH analogues in male patients. Methods. 82 men with non-localised prostate cancer were randomly assigned to receive continuous leuprorelin (LHRH analogue), goserelin (LHRH analogue), cyproterone acetate (steroidal antiandrogen) or close clinical monitoring. These patients underwent cognitive assessments at baseline and before commencement of treatment (77) then 6 months later (65). Results. Compared with baseline assessments, men administered androgen suppression monotherapy performed worse in 2/12 tests of attention and memory.
    [Show full text]
  • Goserelin (Zoladex)
    Goserelin (Zoladex) This booklet explains what goserelin is, when it may be prescribed, how it works and what side effects may occur. Goserelin is the generic (non‑branded) name of the drug and how it’s referred to in this booklet. Its current brand name is Zoladex. This information is by Breast Cancer Care. We are the only specialist UK‑wide charity that supports people affected by breast cancer. We’ve been supporting them, their family and friends and campaigning on their behalf since 1973. Today, we continue to offer reliable information and personal support, over the phone and online, from nurses and people who’ve been there. We also offer local support across the UK. From the moment you notice something isn’t right, through to treatment and beyond, we’re here to help you feel more in control. For breast cancer care, support and information, call us free on 0808 800 6000 or visit breastcancercare.org.uk Visit breastcancercare.org.uk 3 What is goserelin? Goserelin is a type of hormone therapy used to treat breast cancer in pre-menopausal women (women who have not been through the menopause). It is given as an injection into the abdomen (belly). It can also be used to try to preserve fertility during chemotherapy (see page 4). Goserelin as a treatment for breast cancer How does it work? Some breast cancers are stimulated to grow by the hormone oestrogen. Before the menopause, oestrogen is mainly produced in the ovaries. Goserelin switches off this production by interfering with hormone signals from the brain that control how the ovaries work.
    [Show full text]
  • Triptorelin, Goserelin and Leuprorelin for Prostate
    789FM.1 GONADORELIN ANALOGUES (GnRHa): TRIPTORELIN, GOSERELIN, LEUPRORELIN FOR PROSTATE CANCER - AMBER RECOMMENDATION GUIDELINE This guideline provides prescribing and monitoring guidance for triptorelin, goserelin and Leuprorelin use in prostate cancer. It should be read in conjunction with the Summary of Product Characteristics (SPC), available on www.medicines.org.uk/emc, and the BNF. BACKGROUND AND INDICATIONS FOR USE There is no conclusive evidence to suggest that any one GnRHa is more effective or has fewer side effects than another for the treatment of prostate cancer.5, 7-9 Available evidence suggests that GnRHa are similar in effectiveness to surgical castration. They have the same licensed indications in the treatment of prostate cancer (Appendix 1). Appendix 2 compares doses, administration frequency and costs.1-4, 9-13 Triptorelin 22.5 mg (six monthly injection) is the 1st choice GnRHa for treatment of metastatic prostate cancer patients on life-long treatment on the Bucks formulary. This is because it is: • Administered via a smaller sized needle (20 gauge) compared to goserelin LA 10.8 mg (14 gauge), thus minimising discomfort to patients.9 • The least expensive in terms of drug and administration costs (Appendix 2).1-4, 9-13 Triptorelin 22.5 mg (six monthly injection) is not preferred in: • Patients newly initiated GnRHa because the first dose should be a monthly preparation (Decapeptyl® SR 3 mg) in order to check that the product is tolerated prior to changing to the six monthly preparation.14 • Anticoagulated patients. This is because triptorelin is an intramuscular (IM) injection. Subcutaneously administered GnRHa (goserelin or leuprorelin) may be preferable.9 RESPONSIBILITIES Hospital specialist 1.
    [Show full text]
  • DESCRIPTION Vantas™ (Histrelin Implant) Is a Sterile Non-Biodegradable, Diffusion-Controlled Reservoir Drug Delivery System De
    Vantas™ (histrelin implant) PACKAGE INSERT DESCRIPTION Vantas™ (histrelin implant) is a sterile non-biodegradable, diffusion-controlled reservoir drug delivery system designed to deliver histrelin continuously for 12 months upon subcutaneous implantation. The Vantas implant contains 50 mg of histrelin acetate. Histrelin acetate is a synthetic nonapeptide analogue of the naturally occurring gonadotropin releasing hormone (GnRH) or luteinizing hormone releasing hormone (LH-RH). The sterile Vantas implantation device (provided with the implant) is used to insert the implant subcutaneously in the inner aspect of the upper arm. After 12 months, the implant must be removed. At the time the implant is removed, another implant may be inserted to continue therapy. The sterile Vantas ™ implant consists of a 50-mg histrelin acetate drug core inside a non- biodegradable, 3 cm by 3.5 mm cylindrically shaped hydrogel reservoir (Figure A). The drug core also contains the inactive ingredient stearic acid NF. The hydrogel reservoir is a hydrophilic polymer cartridge composed of 2-hydroxyethyl methacrylate, 2-hydroxypropyl methacrylate, trimethylolpropane trimethacrylate, benzoin methyl ether, Perkadox-16, and Triton X-100. The hydrated implant is packaged in a glass vial containing 2.0 mL of 1.8% NaCl solution. The implant is primed for release of the drug upon insertion. Figure A. Vantas Histrelin Implant diagram (not to scale) Hydrogel Reservoir Drug Formulation Histrelin acetate is chemically described as 5-oxo-L-prolyl-L-histidyl-L-tryptophyl-L-seryl-L- tyrosyl-Nt-benzyl-D-histidyl-L-leucyl-L-arginyl-N-ethyl-L-prolinamide acetate (salt) [C66H86N18O12. (1.7-2.8 moles) CH3COOH, (0.6-7.0 moles) H2O], with the molecular weight of 1443.70 (or 1323.50 as histrelin base.
    [Show full text]
  • PE2572 Puberty Blockers
    Puberty Blockers What are puberty Puberty blockers are medicines that block puberty-related hormones that blockers? make your body go through puberty. Starting puberty blockers is a decision that is different for everyone. To make the most informed decision, this handout is meant to help you understand: • What is puberty? • What do puberty blockers do? • What are the changes that will happen to my body? • What are the benefits, risks and costs involved? We will work with you to support the decision that is best for you. You can view a video about puberty blockers at seattlechildrens.org/gender. How does puberty Puberty is the process the body goes through to become capable of begin? making a baby (reproduction), as well as reach adult size and brain development. Puberty starts when your brain tells your pituitary gland to start releasing puberty-related hormones. This happens at different ages for different people. During this time, your body starts to increase the amount of certain puberty-related hormones (Luteinizing Hormone (LH) and Follicle- Stimulating Hormone (FSH). This causes your testicles to start producing testosterone or your ovaries start producing estrogen. These hormones do not cause acne, pubic or armpit hair – those are caused by other hormones. Body changes in • Testicle growth (this improves the body’s ability to make testosterone) people with testicles • Penis growth (without puberty • Pubic hair blockers) • Increased acne, increased armpit and facial hair • Rapid growth (growth spurt) • Voice changes (deepens) Body changes in • Breast changes people with ovaries • Changes in body shape, including fuller hips (without puberty • Menstrual periods start (usually more than 2 years after breast changes blockers) begin) 1 of 6 To Learn More Free Interpreter Services • Adolescent Medicine • In the hospital, ask your nurse.
    [Show full text]
  • Quantity Limits/Daily Dose Limits
    Effective 07/20/21 Alphabetical by Brand Name (when applicable) PA Medical Assistance Fee-for-Service Quantity Limits & Daily Dose Limits Maximum Therapy Class Brand Name Generic Name Daily Dose Limit Antipsychotics, Atypical ABILIFY 1 MG/ML SOLUTION ARIPIPRAZOLE 25 Antipsychotics, Atypical ABILIFY 10 MG DISCMELT ARIPIPRAZOLE 2 Antipsychotics, Atypical ABILIFY 10 MG TABLET ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY 15 MG DISCMELT ARIPIPRAZOLE 2 Antipsychotics, Atypical ABILIFY 15 MG TABLET ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY 2 MG TABLET ARIPIPRAZOLE 2 Antipsychotics, Atypical ABILIFY 20 MG TABLET ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY 30 MG TABLET ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY 5 MG TABLET ARIPIPRAZOLE 1.5 Antipsychotics, Atypical ABILIFY 9.75 MG/1.3 ML INJECTION VIAL ARIPIPRAZOLE 3.9 Antipsychotics, Atypical ABILIFY MAINTENA ER 300 MG SYRINGE ARIPIPRAZOLE 0.04 Antipsychotics, Atypical ABILIFY MAINTENA ER 300 MG VIAL ARIPIPRAZOLE 0.04 Antipsychotics, Atypical ABILIFY MAINTENA ER 400 MG SYRINGE ARIPIPRAZOLE 0.04 Antipsychotics, Atypical ABILIFY MAINTENA ER 400 MG VIAL ARIPIPRAZOLE 0.04 Antipsychotics, Atypical ABILIFY MYCITE 10 MG KIT ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY MYCITE 15 MG KIT ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY MYCITE 2 MG KIT ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY MYCITE 20 MG KIT ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY MYCITE 30 MG KIT ARIPIPRAZOLE 1 Antipsychotics, Atypical ABILIFY MYCITE 5 MG KIT ARIPIPRAZOLE 1 Antivirals, Herpes ABREVA 10%
    [Show full text]
  • Luteinising Hormone-Releasing Hormone (LHRH) Agonists in Prostate Cancer This Bulletin Focuses on Luteinising Hormone-Releasing Hormone (LHRH) Agonists
    B88 | April 2015 | 2.1 Community Interest Company Luteinising hormone-releasing hormone (LHRH) agonists in prostate cancer This bulletin focuses on luteinising hormone-releasing hormone (LHRH) agonists. Currently goserelin and leuprorelin (administered 4 weekly or 12 weekly and monthly or 3 monthly respectively) are the two LHRH agonists used primarily in the management of prostate cancer across England (88% share, ePACT October to December 2014). Triptorelin is also used for prostate cancer and has published data to confirm its efficacy. However triptorelin only accounts for 12% (ePACT October to December 2014) of all LHRH agonist usage. Across England, a switch from 12 weekly goserelin and 3 monthly leuprorelin to 12 weekly or 6 monthly triptorelin could result in an annual saving of £6.8 million (ePACT October to December 2014). Support materials (including the secondary care bulletin: Bulletin 28 Secondary care KPI support bulletins. Gonadorelin analogues – reduced usage of Zoladex) are available at http://www.prescqipp.info Recommendations • Engage and establish opinion with local Trust urologists on preferred formulary choices of LHRH agonists. This should take into account dosage intervals, administration, product price, and fees paid for administration. Local decision making may also be affected by local discounts and rebate scheme activity. • 3 monthly and 6 monthly triptorelin and 3 monthly leuprorelin are the preferred cost effective LHRH agonists for prostate cancer in new patients. • Switch guidance will need to be agreed by local Trust urologists for existing patients and should be considered at the next clinic appointment. • Use 12 weekly/3 monthly or 6 monthly injections in preference to 4 weekly/monthly injections to support administration, convenience to the patient and costs.
    [Show full text]